Report Description Table of Contents Malignant Mesothelioma Therapeutics Market Size, Share, Treatment Landscape and Forecast, 2026-2032 2025 Market Size USD 0.64 billion 2032 Forecast USD 1.03 billion 2026-2032 CAGR 7.0% What Is the Current Malignant Mesothelioma Therapeutics Market Size and How Is First-Line Care Changing? The Global Malignant Mesothelioma Therapeutics Market was valued at USD 0.64 billion in 2025 and is projected to reach USD 1.03 billion by 2032, expanding at a CAGR of 7.0% during 2026-2032, according to Strategic Market Research. Malignant mesothelioma therapeutics are systemic medicines and selected multimodal treatments used primarily to manage pleural mesothelioma, an aggressive cancer strongly associated with asbestos exposure. The commercial treatment population is relatively small but clinically intensive: GLOBOCAN 2022 estimated 30,633 new mesothelioma cases worldwide, while U.S. Cancer Statistics recorded 2,669 cases in 2022. CDC data covering 63,620 U.S. cases diagnosed during 2003–2022 show that 81.0% originated in the pleura and 11.1% in the peritoneum, making pleural disease the principal pharmaceutical treatment population. First-line care has moved beyond platinum-pemetrexed alone. The FDA approved Bristol Myers Squibb's nivolumab plus ipilimumab for unresectable MPM in 2020 and Merck's pembrolizumab with pemetrexed and platinum chemotherapy in September 2024. Nivolumab and pembrolizumab block PD-1, while ipilimumab blocks CTLA-4, creating different checkpoint strategies. Five-year CheckMate 743 follow-up reported overall survival of 14% with nivolumab-ipilimumab versus 6% with chemotherapy. ASCO's 2025 guideline recommends nivolumab-ipilimumab as a first-line option and supports pembrolizumab chemoimmunotherapy. The late-stage pipeline is more selective: AstraZeneca's phase III eVOLVE-Meso study of volrustomig remains active but not recruiting, whereas Polaris voluntarily withdrew the U.S. BLA for pegargiminase in May 2026, materially reducing its near-term U.S. regulatory visibility. What Are the Key Segment Takeaways From the Malignant Mesothelioma Therapeutics Market? Treatment Type: Chemotherapy accounted for 48.0% of the market, valued at USD 0.307 billion in 2025, and is projected to grow at a CAGR of 4.5% during 2026–2032. Immunotherapy represented 35.0% of the market, equivalent to USD 0.224 billion in 2025, and is expected to expand at a CAGR of 10.2%. Targeted Therapy held a 7.0% market share, valued at USD 0.045 billion in 2025, and is projected to register a CAGR of 8.4%. Other Systemic Therapies accounted for 10.0% of the market, corresponding to USD 0.064 billion in 2025, and are expected to grow at a CAGR of 5.1%. Drug: Pemetrexed accounted for 26.0% of the market, valued at USD 0.166 billion in 2025, and is projected to grow at a CAGR of 5.9% during 2026–2032. Cisplatin represented 15.0% of the market, equivalent to USD 0.096 billion in 2025, and is expected to expand at a CAGR of 4.1%. Carboplatin held a 12.0% market share, valued at USD 0.077 billion in 2025, and is projected to register a CAGR of 4.5%. Nivolumab accounted for 14.0% of the market, corresponding to USD 0.090 billion in 2025, and is expected to grow at a CAGR of 11.3%. Ipilimumab represented 8.0% of the market, valued at USD 0.051 billion in 2025, and is projected to expand at a CAGR of 10.6%. Pembrolizumab accounted for 7.0% of the market, equivalent to USD 0.045 billion in 2025, and is expected to grow at a CAGR of 9.7%. Bevacizumab held a 5.0% market share, valued at USD 0.032 billion in 2025, and is projected to register a CAGR of 6.9%. Gemcitabine represented 4.0% of the market, corresponding to USD 0.026 billion in 2025, and is expected to grow at a CAGR of 4.8%. Vinorelbine accounted for 3.0% of the market, valued at USD 0.019 billion in 2025, and is projected to expand at a CAGR of 3.9%. Other drugs collectively represented 6.0% of the market, equivalent to USD 0.038 billion in 2025, and are expected to grow at a CAGR of 6.6%. Route of Administration: Intravenous/Parenteral administration dominated with 88.0% of the market, valued at USD 0.563 billion in 2025, and is projected to grow at a CAGR of 7.2% during 2026–2032. Oral administration accounted for 5.0% of the market, equivalent to USD 0.032 billion in 2025, and is expected to expand at a CAGR of 6.1%. Intracavitary and Other Routes represented 7.0% of the market, valued at USD 0.045 billion in 2025, and are projected to register a CAGR of 5.1%. End User: Hospitals & Cancer Centers accounted for 68.0% of the market, valued at USD 0.435 billion in 2025, and are projected to grow at a CAGR of 6.8% during 2026–2032. Specialty Oncology Clinics represented 22.0% of the market, equivalent to USD 0.141 billion in 2025, and are expected to expand at a CAGR of 7.4%. Ambulatory Infusion Centers held a 10.0% market share, valued at USD 0.064 billion in 2025, and are projected to grow at a CAGR of 7.9%. Geography: North America accounted for 41.0% of the market, valued at USD 0.262 billion in 2025, and is projected to grow at a CAGR of 6.9% during 2026–2032. Europe represented 30.0% of the market, equivalent to USD 0.192 billion in 2025, and is expected to expand at a CAGR of 6.1%. Asia-Pacific accounted for 22.0% of the market, valued at USD 0.141 billion in 2025, and is projected to register the fastest growth at a CAGR of 8.9%. Rest of World represented 7.0% of the market, corresponding to USD 0.045 billion in 2025, and is projected to expand at an approximately 6.1% weighted CAGR. What Do Treatment-Type and Drug Segments Reveal About Revenue Migration in the Malignant Mesothelioma Therapeutics Market? Chemotherapy accounted for 48.0% of the market, or USD 0.307 billion, in 2025 and is projected to grow at a 4.5% CAGR. Its position reflects continued use of platinum-pemetrexed both as standalone therapy and as the backbone of pembrolizumab chemoimmunotherapy. Immunotherapy represented 35.0%, or USD 0.224 billion, in 2025 and is forecast to expand at 10.2%. Bristol Myers Squibb's nivolumab-ipilimumab and Merck's pembrolizumab-based regimen have created two commercially distinct first-line strategies: chemotherapy-free dual checkpoint blockade and chemoimmunotherapy. Targeted Therapy held 7.0%, or USD 0.045 billion, in 2025 and is projected to grow at 8.4%. Current commercial relevance is concentrated in selected anti-angiogenic use such as bevacizumab-containing regimens. Investigational metabolic therapies should not be counted as approved revenue contributors. Other Systemic Therapies accounted for 10.0%, or USD 0.064 billion, in 2025 and are expected to expand at 5.1%. This category covers selected later-line cytotoxics and physician-directed systemic options not separately broken out in the SMR drug segmentation. Pemetrexed led individual drugs with 26.0% of the market, representing USD 0.166 billion in 2025, and is projected to grow at 5.9%. Its position remains resilient because immunotherapy adoption can preserve rather than displace pemetrexed when pembrolizumab is added to platinum-pemetrexed. Cisplatin accounted for 15.0%, or USD 0.096 billion, in 2025 and is projected to grow at 4.1%. It remains an established pemetrexed partner, although toxicity and the older treatment population can favor alternative regimens. Carboplatin represented 12.0%, or USD 0.077 billion, and is expected to grow at 4.5%. Its practical role is reinforced by use in patients for whom cisplatin is less suitable; Australia's 2025 registry reported a median mesothelioma diagnosis age of 78 years. Nivolumab held 14.0%, or USD 0.090 billion, in 2025 and is projected to expand at 11.3%, the fastest supplied drug CAGR. Its first-line FDA approval with ipilimumab and durable five-year CheckMate 743 survival evidence support continued market share gains. Ipilimumab represented 8.0%, or USD 0.051 billion, in 2025 and is forecast to grow at 10.6%. Its mesothelioma value is tied to combination use with nivolumab, where CTLA-4 blockade complements PD-1 inhibition. Pembrolizumab accounted for 7.0%, or USD 0.045 billion, in 2025 and is projected to grow at 9.7%. In KEYNOTE-483, pembrolizumab plus chemotherapy produced median overall survival of 17.3 months versus 16.1 months and an objective response rate of 52% versus 29% with chemotherapy alone. Bevacizumab held 5.0%, or USD 0.032 billion, in 2025 and is projected to grow at 6.9%. It inhibits VEGF-driven angiogenesis and remains a selected combination option, although it does not have a specific FDA mesothelioma indication. Gemcitabine accounted for 4.0%, or USD 0.026 billion, in 2025 and is forecast to grow at 4.8%. Its commercial role is mainly in selected recurrent or later-line treatment rather than the high-value first-line checkpoint setting. Vinorelbine represented 3.0%, or USD 0.019 billion, and is projected to grow at 3.9%. It retains a limited role after prior treatment, resulting in slower expansion than checkpoint inhibitors. Other Drugs accounted for 6.0%, or USD 0.038 billion, in 2025 and are forecast to grow at 6.6%, covering less frequently used systemic agents and evolving treatment options after progression. How Are Administration Routes and Care Settings Shaping the Malignant Mesothelioma Therapeutics Market? Intravenous/parenteral administration dominated with 88.0% of the market, or USD 0.563 billion, in 2025 and a 7.2% CAGR. Pemetrexed, platinum drugs and major checkpoint inhibitors are delivered parenterally. FDA approval of subcutaneous Keytruda Qlex in September 2025 introduces greater administration flexibility, although mesothelioma chemoimmunotherapy still requires infused chemotherapy. Oral therapy represented 5.0%, or USD 0.032 billion, in 2025 and is projected to grow at 6.1%. The share reflects less frequently used systemic products captured in SMR's route classification; no oral drug currently defines the first-line standard. Intracavitary and other routes accounted for 7.0%, or USD 0.045 billion, and a 5.1% CAGR. NCI notes that intrapleural and intraperitoneal approaches have shown temporary control in small studies, but their role remains specialist and incompletely defined. Hospitals and cancer centers accounted for 68.0%, or USD 0.435 billion, in 2025 and are projected to expand at 6.8%. Multidisciplinary thoracic oncology, infusion, pathology review and immune-related toxicity management keep these centers central to treatment. Specialty oncology clinics represented 22.0%, or USD 0.141 billion, and a 7.4% CAGR. They support repeated systemic therapy and outpatient follow-up where infusion capability and reimbursement permit. Ambulatory infusion centers held 10.0%, or USD 0.064 billion, in 2025 and are projected to grow at 7.9%, the fastest end-user rate, as repeated infusion cycles increasingly use outpatient infrastructure when clinically appropriate. Which Late-Stage Programs Could Change the Malignant Mesothelioma Therapeutics Market? AstraZeneca's volrustomig is the most important active late-stage competitive program. The PD-1/CTLA-4 bispecific antibody is being evaluated with carboplatin and pemetrexed in the phase III eVOLVE-Meso trial. ClinicalTrials.gov lists 863 actual participants, active but not recruiting status, and estimated primary completion in November 2028. Its comparator can include nivolumab-ipilimumab, meaning any future differentiation must be demonstrated against a modern immunotherapy standard rather than chemotherapy alone. Pegargiminase remains clinically relevant but has a weaker U.S. commercial outlook. The ATOMIC-Meso study showed median overall survival of 9.3 months with pegargiminase plus chemotherapy versus 7.7 months with chemotherapy control in non-epithelioid disease. However, Polaris voluntarily withdrew its U.S. BLA in May 2026 and FDA continues to list pegargiminase as not approved for the orphan mesothelioma indication. The program should therefore be treated as an asset with uncertain future regulatory positioning, not as a near-term U.S. launch candidate. Durvalumab-based chemoimmunotherapy also illustrates pipeline risk. NCI discusses durvalumab with platinum-pemetrexed as a systemic option based on clinical evidence, but durvalumab has no FDA mesothelioma indication and the phase III DREAM3R trial did not meet its primary overall-survival endpoint. This raises the competitive threshold for additional checkpoint combinations. How Are Reimbursement and Regional Access Influencing the Malignant Mesothelioma Therapeutics Market? Real-world reimbursement data show why a rare cancer can still create meaningful drug expenditure. Australia's PBS reported 748 prevalent nivolumab-ipilimumab users at a cost of AUD 58 million in the first year after listing and 742 users at AUD 59 million in the second year. In England, NICE recommends nivolumab-ipilimumab for eligible untreated unresectable MPM under a commercial arrangement, while its January 2026 appraisal of pembrolizumab plus chemotherapy was terminated because Merck did not proceed with an evidence submission. North America accounted for 41.0% of the market, or USD 0.262 billion, in 2025 and is projected to grow at 6.9%. FDA availability of both nivolumab-ipilimumab and pembrolizumab chemoimmunotherapy, combined with specialist thoracic oncology infrastructure, supports the region's leading commercial position despite declining U.S. incidence. Europe represented 30.0%, or USD 0.192 billion, and a 6.1% CAGR. GLOBOCAN-based analysis indicates Europe accounted for 48.1% of global mesothelioma cases in 2022, but national HTA and reimbursement decisions create uneven commercial access across countries. Asia Pacific accounted for 22.0%, or USD 0.141 billion, and is projected to grow at 8.9%. Australia reported 627 cases diagnosed in 2025 as of May 1, 2026, with a median diagnosis age of 78 years, while PBS utilization demonstrates established use of high-value checkpoint therapy. SMR allocates the supplied 7.0% Rest-of-World share as 4.0% Latin America and 3.0% Middle East & Africa; together, the two regions preserve the original 7.0% share and approximately 6.1% weighted CAGR. Latin America is estimated by SMR at 4.0%, or USD 0.026 billion, in 2025 with a 6.4% CAGR. The market remains smaller and more concentrated in specialist oncology systems, with regional licensing and access strategies more important than broad population coverage. Middle East & Africa is estimated by SMR at 3.0%, or USD 0.019 billion, with a 5.7% CAGR. Commercial activity is concentrated in higher-resource cancer systems, particularly GCC markets, while broader access remains limited by specialist infrastructure and reimbursement. Which Companies Are Best Positioned in the Malignant Mesothelioma Therapeutics Market Through 2032? Competition is centered on survival durability, histology-specific benefit, chemotherapy-free versus chemoimmunotherapy positioning, route flexibility and late-stage pipeline differentiation. Reimbursement and geographic commercialization matter disproportionately because the addressable patient population is small and each eligible treated patient carries relatively high therapeutic value. Bristol Myers Squibb Bristol Myers Squibb competes through Opdivo (nivolumab) plus Yervoy (ipilimumab), the FDA-approved chemotherapy-free first-line combination for unresectable MPM. The key differentiation is mature survival evidence and strong guideline positioning across histologies, with particular strategic importance in non-epithelioid disease. Merck & Co. Merck's Keytruda (pembrolizumab) competes through combination with pemetrexed and platinum chemotherapy. Its FDA approval created a first-line chemoimmunotherapy alternative rather than a direct copy of the BMS approach. Keytruda Qlex adds subcutaneous administration flexibility for pembrolizumab-covered solid-tumor indications. AstraZeneca AstraZeneca's mesothelioma position is pipeline led. Volrustomig is in phase III eVOLVE-Meso development, while the negative DREAM3R outcome reduces the commercial relevance of durvalumab-based expansion in this indication. Novocure Novocure participates through Optune Lua, an FDA HDE-approved Tumor Treating Fields device used with pemetrexed and platinum chemotherapy in unresectable MPM. It is strategically relevant as a treatment-pathway adjunct, but its device revenue is outside the SMR pharmaceutical/biologic market sizing used in this report. Polaris Group Polaris retains clinical evidence for pegargiminase in non-epithelioid disease, but the May 2026 U.S. BLA withdrawal materially changes its competitive outlook. Future value depends on any revised development plan or non-U.S. regulatory strategy rather than near-term FDA commercialization. What Will Shape the Malignant Mesothelioma Therapeutics Market Through 2032? The central market shift is revenue migration rather than rapid patient-volume expansion. Chemotherapy remains the largest treatment category in 2025, but immunotherapy's 10.2% CAGR is more than twice chemotherapy's 4.5%, while nivolumab, ipilimumab and pembrolizumab all expand faster than the global market. The principal upside lies in longer treatment duration, greater checkpoint penetration, successful next-generation combinations and broader reimbursement. The main constraints are declining incidence in some mature asbestos-regulated markets, an older and often comorbid patient population, uneven access to high-cost biologics and the high clinical threshold facing new entrants. The strongest strategic opportunities will therefore come from therapies that improve outcomes in difficult histologies, create value after progression, reduce treatment burden or secure differentiated reimbursement rather than from simple additions to an already crowded checkpoint landscape. Malignant Mesothelioma Therapeutics Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 0.64 Billion Revenue Forecast in 2032 USD 1.03 Billion Overall Growth Rate CAGR of 7.0% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Treatment Type, By Drug, By Route of Administration, By End User, By Geography By Treatment Type Chemotherapy, Immunotherapy, Targeted Therapy, Other Systemic Therapies By Drug Pemetrexed, Cisplatin, Carboplatin, Nivolumab, Ipilimumab, Pembrolizumab, Bevacizumab, Gemcitabine, Vinorelbine, Other Drugs By Route of Administration Intravenous/Parenteral, Oral, Intracavitary and Other Routes By End User Hospitals & Cancer Centers, Specialty Oncology Clinics, Ambulatory Infusion Centers By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Rising adoption of first-line checkpoint immunotherapy, expanding use of chemoimmunotherapy regimens, improving reimbursement for high-value oncology biologics, continued development of next-generation immunotherapy combinations Customization Option Available upon request Frequently Asked Question About This Report Q1. What are the main factors driving market growth? A1. Growth is being driven mainly by wider use of checkpoint inhibitors, longer treatment duration and greater reimbursement for high-value systemic therapies. Revenue is shifting toward immunotherapy even though chemotherapy remains an important treatment backbone. Q2. What are the latest innovations transforming the industry? A2. Dual checkpoint blockade, chemoimmunotherapy and bispecific immune therapies are reshaping treatment development. Volrustomig is one of the most important late-stage programs because it combines PD-1 and CTLA-4 targeting within a single investigational antibody. Q3. What is driving the shift toward advanced solutions in the industry? A3. Clinicians need treatments that improve survival beyond conventional platinum-pemetrexed therapy, particularly in difficult histologies and unresectable disease. This has increased adoption of nivolumab-ipilimumab and pembrolizumab-based combinations while raising the clinical threshold for future entrants. Q4. Which region currently leads the market and why? A4. North America leads because patients have access to multiple FDA-approved first-line immunotherapy strategies and established thoracic oncology infrastructure. Specialist cancer centers and reimbursement for high-value biologics further support the region’s commercial position. Q5. How is competition evolving among key players in the market? A5. Competition is moving beyond basic chemotherapy toward survival durability, histology-specific benefit and chemotherapy-free versus chemoimmunotherapy positioning. Bristol Myers Squibb and Merck lead current first-line immunotherapy competition, while AstraZeneca is pursuing next-generation differentiation through volrustomig. Q6. What are the most promising applications expected to grow in the industry? A6. First-line immunotherapy remains the strongest commercial opportunity, particularly for patients with unresectable pleural disease. Additional opportunities exist in non-epithelioid disease and post-progression treatment, where therapeutic options remain limited and new mechanisms could provide meaningful differentiation. Q7. How will the market evolve over the next few years? A7. Immunotherapy is expected to capture a larger share of treatment revenue while chemotherapy continues as both a standalone option and a backbone for combination regimens. Future growth will depend increasingly on next-generation combinations, broader reimbursement and therapies that improve outcomes in difficult-to-treat patients. Sources and Evidence Base 1. IARC GLOBOCAN 2022 2. CDC U.S. Cancer Statistics 3. NCI Mesothelioma PDQ 4. FDA MPM pembrolizumab approval | Keytruda Qlex 5. FDA nivolumab-ipilimumab record | pegargiminase status 6. ASCO guideline | CheckMate 743 7. eVOLVE-Meso | DREAM3R 8. ATOMIC-Meso 9. AIHW 2025 registry | Australian PBS 10. NICE TA818 | TA1125 11. Polaris BLA withdrawal | AACR DREAM3R Table of Contents - Global Malignant Mesothelioma Therapeutics Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Treatment Type, Drug, Route of Administration, End User, and Geography Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Treatment Type, Drug, Route of Administration, End User, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Treatment Type, Drug, Route of Administration, End User, and Geography Investment Opportunities in the Malignant Mesothelioma Therapeutics Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in First-Line Checkpoint Immunotherapy, Chemoimmunotherapy, Targeted Therapy, Route Flexibility, Specialist Oncology Care, and Next-Generation Combination Therapies Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Malignant Mesothelioma Therapeutics in Pleural Mesothelioma and Multimodal Oncology Care Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory, Reimbursement, and Clinical Development Factors Role of First-Line Checkpoint Immunotherapy, Chemoimmunotherapy, and Targeted Therapy in Market Expansion Treatment Access, Specialist Oncology Infrastructure, and Patient-Centric Administration Trends in Therapeutic Adoption Global Malignant Mesothelioma Therapeutics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type: Chemotherapy Immunotherapy Targeted Therapy Other Systemic Therapies Market Analysis by Drug: Pemetrexed Cisplatin Carboplatin Nivolumab Ipilimumab Pembrolizumab Bevacizumab Gemcitabine Vinorelbine Other Drugs Market Analysis by Route of Administration: Intravenous/Parenteral Oral Intracavitary and Other Routes Market Analysis by End User: Hospitals & Cancer Centers Specialty Oncology Clinics Ambulatory Infusion Centers Market Analysis by Geography: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Malignant Mesothelioma Therapeutics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug, Route of Administration, and End User Country-Level Breakdown: United States Canada Mexico Europe Malignant Mesothelioma Therapeutics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug, Route of Administration, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Malignant Mesothelioma Therapeutics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug, Route of Administration, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Malignant Mesothelioma Therapeutics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug, Route of Administration, and End User Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Malignant Mesothelioma Therapeutics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Drug, Route of Administration, and End User Country-Level Breakdown: GCC Countries Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Bristol Myers Squibb Merck & Co. AstraZeneca Novocure Polaris Group Roche Eli Lilly and Company Teva Pharmaceuticals Sun Pharmaceutical Industries Ltd. Competitive Landscape and Strategic Insights Benchmarking Based on Treatment Portfolio, First-Line Immunotherapy Positioning, Clinical Evidence, Regulatory Strength, Distribution Network, Oncology Infrastructure, and Regional Presence Therapeutic Portfolio and Compliance Capability Analysis Checkpoint Immunotherapy Positioning Chemoimmunotherapy and Combination Treatment Competitiveness Targeted Therapy and Systemic Treatment Strategy Analysis Administration Route Flexibility and Specialist Oncology Care Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Treatment Type, Drug, Route of Administration, End User, and Geography (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Regulatory, Reimbursement, and Access Analysis Therapeutic Adoption Trends Across Chemotherapy, Immunotherapy, Targeted Therapy, and Other Systemic Therapies List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Treatment Type, Drug, Route of Administration, End User, and Geography (2025 vs. 2032) Global Malignant Mesothelioma Therapeutics Ecosystem and Value Chain Analysis